Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study.
Donaldson SH, Corcoran TE, Pilewski JM, Laube BL, Mogayzel P, Ceppe A, Wu J, Zeman K, Rowe SM, Nichols DP, Gifford AH, Bennett WD, Mayer-Hamblett N; SIMPLIFY MCC Study teams. Donaldson SH, et al. Among authors: rowe sm. J Cyst Fibros. 2024 Feb 13:S1569-1993(24)00018-3. doi: 10.1016/j.jcf.2024.02.003. Online ahead of print. J Cyst Fibros. 2024. PMID: 38355350
Bioelectric effects of quinine on polarized airway epithelial cells.
Bates E, Miller S, Alexander M, Mazur M, Fortenberry JA, Bebok Z, Sorscher EJ, Rowe SM. Bates E, et al. Among authors: rowe sm. J Cyst Fibros. 2007 Sep;6(5):351-9. doi: 10.1016/j.jcf.2007.01.001. Epub 2007 Feb 27. J Cyst Fibros. 2007. PMID: 17329172 Free PMC article.
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B. Clancy JP, et al. Among authors: rowe sm. Am J Respir Cell Mol Biol. 2007 Jul;37(1):57-66. doi: 10.1165/rcmb.2006-0173OC. Epub 2007 Mar 8. Am J Respir Cell Mol Biol. 2007. PMID: 17347447 Free PMC article. Clinical Trial.
An international randomized multicenter comparison of nasal potential difference techniques.
Solomon GM, Konstan MW, Wilschanski M, Billings J, Sermet-Gaudelus I, Accurso F, Vermeulen F, Levin E, Hathorne H, Reeves G, Sabbatini G, Hill A, Mayer-Hamblett N, Ashlock M, Clancy JP, Rowe SM. Solomon GM, et al. Among authors: rowe sm. Chest. 2010 Oct;138(4):919-28. doi: 10.1378/chest.10-0179. Epub 2010 May 14. Chest. 2010. PMID: 20472865 Free PMC article. Clinical Trial.
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW. Accurso FJ, et al. Among authors: rowe sm. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825. N Engl J Med. 2010. PMID: 21083385 Free PMC article. Clinical Trial.
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Clancy JP, et al. Among authors: rowe sm. Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8. Thorax. 2012. PMID: 21825083 Free PMC article. Clinical Trial.
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group. Ramsey BW, et al. Among authors: rowe sm. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185. N Engl J Med. 2011. PMID: 22047557 Free PMC article. Clinical Trial.
Evaluating the predictive ability of sweat chloride.
Heltshe SL, Rowe SM, Mayer-Hamblett N. Heltshe SL, et al. Among authors: rowe sm. J Cyst Fibros. 2014 Jan;13(1):118. doi: 10.1016/j.jcf.2013.07.002. Epub 2013 Aug 3. J Cyst Fibros. 2014. PMID: 23920003 Free article. No abstract available.
Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.
Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, Accurso FJ, Dong Q, Ordoñez CL, Stone AJ, Olson ER, Clancy JP; VX06-770-101 Study Group. Rowe SM, et al. PLoS One. 2013 Jul 26;8(7):e66955. doi: 10.1371/journal.pone.0066955. Print 2013. PLoS One. 2013. PMID: 23922647 Free PMC article. Clinical Trial.
328 results